Differences in immune responses due to age, sex, and genetics

Over the course of our life, we are continuously exposed to pathogens such as viruses and bacteria, meaning that our immune system is constantly at work. When stimulated by either pathogen or vaccine, the immune system notably mounts what is known as a "humoral response", which corresponds to the production of antibodies that can help fight infections and provide long-term protection.

The intensity of humoral responses differs from person to person. Understanding why, and identifying the specific determinants of this variability could help us improve vaccines, predict a person's susceptibility to a particular pathogen, or get a deeper understanding of autoimmune diseases.

In a new study published in Genome Medicine, the lab of Jacques Fellay at EPFL, working with the Pasteur Institute in Paris, have examined the humoral responses of 1,000 healthy people to common infections and vaccines. The scientists measured antibody responses to fifteen antigens (molecules that trigger humoral responses) from twelve infectious agents: cytomegalovirus, Epstein-Barr virus, herpes simplex virus 1 and 2, varicella zoster virus, influenza A virus, measles, mumps, rubella, and hepatitis B virus, Helicobacter pylori and Toxoplasma gondii.

In order to assess the importance of non-genetic factors, the researchers looked at the impact of numerous demographic variables. They identified age and sex as the most important determinants of humoral response, with older individuals and women showing stronger antibody responses against most antigens.

For the genetic factors, the scientists performed genome-wide association studies, which allow the exploration of the potential impact of genetic variation throughout the human genome. The studies showed that differences in response to Epstein-Barr virus and rubella associate with variation in the human leucocyte antigen (HLA) gene region, which encodes proteins involved in the recognition of foreign antigens.

"To combat infectious and autoimmune diseases, we need to better understand variation in the healthy immune response", says Jacques Fellay. "Our study is a necessary first step toward individualized healthcare in infection and immunity".

Petar Scepanovic, Cécile Alanio, Christian Hammer, Flavia Hodel, Jacob Bergstedt, Etienne Patin, Christian W Thorball, Nimisha Chaturvedi, Bruno Charbit, Laurent Abel, Lluis Quintana-Murci, Darragh Duffy, Matthew L Albert, Jacques Fellay, The Milieu Intérieur Consortium.
Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines.
Genome Medicine201810:59. doi: 10.1186/s13073-018-0568-8.

Most Popular Now

Forxiga receives positive EU CHMP opinion for the …

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxi...

US FDA grants Breakthrough Therapy Designation for…

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Ther...

New pill can deliver insulin

An MIT-led research team has developed a drug capsule that could be used to deliver oral doses of insulin, potentially replacing the injections that people with type 2 di...

Merck to expand US biopharmaceutical R&D facil…

Merck, a leading science and technology company, today announced a $70 million investment to expand its state of the art research and development (R&D) facility in Biller...

Pfizer receives positive CHMP opinion for Vizimpro…

Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending V...

Cannabinoid compounds may inhibit growth of colon …

Medical marijuana has gained attention in recent years for its potential to relieve pain and short-term anxiety and depression. Now, Penn State College of Medicine resear...

Merck Granted U.S. Patent for novel combination of…

Merck, a leading science and technology company, today announced that it has been granted Patent No. US 10,193,695 by the United States Patent and Trademark Office (USPTO...

Simple drug combination creates new neurons from n…

A simple drug cocktail that converts cells neighboring damaged neurons into functional new neurons could potentially be used to treat stroke, Alzheimer's disease, and bra...

The Union for International Cancer Control and Pfi…

In conjunction with World Cancer Day, the Union for International Cancer Control (UICC) and Pfizer Inc. announce the third round of the Seeding Progress And Resources for...

Pfizer and Lilly announce top-line results from se…

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients...

Merck and Tencent announce collaboration on intell…

Merck, a leading science and technology company, signed a strategic collaboration agreement with Tencent, a leading provider of Internet value added services. The collabo...

New insight into cell receptors opens the way for …

New research on how cancer mutations influence a certain type of receptor on the cell membrane opens the way for the development of tailored drugs for certain cancers, su...